

⁵
39.

(NEW CLAIM)

The method of Claim ¹25, wherein the undesired angiogenesis is associated with macular degeneration.

⁶
40.

(NEW CLAIM)

The method of Claim ¹25, wherein the undesired angiogenesis is associated with corneal neovascularization.


REMARKS

The present invention is directed to compounds capable of inhibiting undesired angiogenesis. Support for the method of Claim 25 is taught in Applicant's specification and the compound is specifically disclosed on pages 12-14.

Applicant respectfully submits that the subject matter of Claims 25 through 40 is supported by the specification. Applicant believes that the claims are in condition for allowance. A Notice of Allowance is therefore respectfully solicited. If the Examiner believes any informalities remain in the application that may be corrected by Examiner's Amendment, or there are any other issues that can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 818-3700 is respectfully solicited.

Respectfully submitted,

JONES & ASKEW



By: Mary Anthony Merchant, Ph.D.
Registration No. P39,771

37th Floor
191 Peachtree Street, N.E.
Atlanta, Georgia 30303-1769
(404) 818-3700
Our File: 05213-0113